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Abstract
A large number of anti-cancer chemotherapeutics target DNA topoisomerases. Etoposide
is a specific topoisomerase II poison which causes reversible double strand DNA breaks. The
focus of this project is to analyze the repair of DNA damage induced by etoposide.. Double
strand DNA break repair is mediated by through either non-homologous end joining (NHEJ) or
homologous recombination. NHEJ repairs through direct ligation of a double stranded break
while homologous recombination utilizes a homologous template to recover the wild type
sequence. A reporter cassette, RYDR-GFP, has been stably integrated into HeLa cells. This
reporter contains an ultra-high affinity topoisomerase II cleavage site (RY) placed in the middle
of a mutant GFP sequence. Flanking this sequence is a corresponding stretch of wild type GFP
that is used as template to repair the break and restore gene function yielding GFP positive cells.
Titrations with etoposide have shown that a logarithmic increase in drug concentration yields a
corresponding increase in repair through homologous recombination (HR). This result
demonstrates that topoisomerase II mediated damage is efficiently repaired by the process of HR.
To examine NHEJ repair, a doxycycline inducible, stably integrated NHEJ HeLa cell reporter
cassette was also evaluated. The data indicates that repair of topoisomerase II mediated DNA
damage occurs more efficiently through the HR pathway. Collectively, the data suggests that
tumor cells proficient in HR repair may effectively elude treatment by topoisomerase II targeting
drugs.
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Chapter One: Introduction
Topoisomerase poisons are widely used as anti-cancer chemotherapeutics [2].
Topoisomerase II (topoII) is the target for many anti-cancer agents because cancer cells have
increased mitotic activity, requiring an increase in topoII expression.
Topoisomerase IIa Mechanism
The role of topoIIis in relaxation, decatanation, and unwinding DNA during replication and
cellular division (Figure 1). A prime example of topoII catalytic activity is during DNA
replication when the replication fork melts the DNA hydrogen bonds between base pairs. As a
result, the DNA preceding the replication fork begins to wind into a highly taut coil called a
supercoil. If left alone, this negative supercoiling can be so severe as to fracture the DNA itself,
thereby creating a genotoxic event [2]. TopoII relaxes the supercoiling.
TopoII is homodimer with a Mg2+ cation in each dimer. TopoII conformationally exists
as closed or open clamps dependent upon ATP binding. ATP binding switches open to closed
clamp formation. In each subunit, the Mg2+ cation stabilizes, in humans, the tyrosine – 804
residue in allowing a nucleophillic attack of the 5’ phosphodiester bond [2]. The mechanism is
repeated on both sides of the double helix. TopoII is now covalently bound creating a proteinDNA adduct with a double stranded break (DSB). Transient strand passage translocates the uncut
strand through the DSB. Within the active site, the dissociated ends are religated. ATP
hydrolysis then switches the homodimer to the open conformation. This mechanism is
equilibrated and can either increase or decrease the linking number by two. The isozyme
topoIIis not mitotically stimulated and is poorly understood, however shares this mechanism
[2] (Figure 1).
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Topoisomerase I Mechanism
Topoisomerase I (topoI) has importance in mitotic, transcription, and promoter regulation
[2]. TopoI does not require ATPase activity. A tyrosine residue performs a nucleophillic attack
on the 5’ phosphodiester bond, creating a single stranded gap. TopoI transfers the free 3’ end
about the intact strand and religates the gap within the catalytic site. The topoI mechanism is in
equilibrium, allowing for the increase or decrease in linking number by one.

Figure 2 - TopoII Cleavage
Complex Repair [4].
Figure
- A.
Figure11–
A.Topoisomerase
TopoisomeraseIIIIPoison;
Poison;B.
B.
Topoisomerase
TopoisomeraseIIIIEnzyme
EnzymeMechanism
Mechanism[2]
[2]
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Topoisomerase II Poisons
TopoII poisons such as etoposide (VP16) stabilize enzyme/DNA cleavages and fragment the
genome (Figure 1). Many topoII agents are in clinical use and are FDA approved. Therefore,
it is vital that we understand how topoII breaks are repaired. VP16 itself is a widely used
chemotherapeutic agent [5].
Chemotherapy sometimes requires high dosages of topoII agent in order to ensure that
DNA damage does not undergo repair, as the cleavage complex is a transient and reversible
event [2]. The stabilized DSB created by topoII poisons increase the half life of the cleavage
complex. DNA/topoII complexes are processed by the 26S proteosome, a macromolecular
structure that degrades ubiquitinated proteins, thus removing the topoII polypeptide portion and
leaving a DSB (Figure 2) [4]. Recent studies further indicate that the removal of the topoII
protein can be performed through CtIP and the phosphodiesterases TDP1 and TDP2 [9]. If the
DNA damage is not efficiently repaired, the cell will undergo apoptosis. This could possibly
reduce the amount of agent needed to fight the malignancy. Information on the repair process
can lead to new strategies that can inhibit the reversal of topoII mediated DNA damage,
thereby minimizing patient side effects through the increase of drug efficacy.
DSB Repair Pathways
DSBs are common events. The dissociated ends can reassociate indiscriminately, differing in
sequence from the wild type. The DSB ultimately can lead to chromosomal translocations [7].
To circumvent this, cells evolved two known mechanisms to correct the DSB, non-homologous
end joining (NHEJ) and homologous recombination (HR).

3

NHEJ is the main pathway by which healthy cells repair from DSBs; however this can alter
gene regulation or expression (Figure 3). The process involves the direct ligation of a DSB
without regard to sequence homology or cell cycle [12]. NHEJ is a low fidelity, high mutation
prone pathway, but repairs DSBs rapidly [12]. Ku, a heterodimer of Ku70 and Ku80, recognizes
the DSB and initiates the NHEJ repair pathway [12]. The Ku protein attracts DNA-PKcs forming
a holoenzyme and autophosphorylates itself, possibly providing the energy needed for the
subsequent blunt ligation. NHEJ provides genomic stability with a half life of 30 minutes [12].
HR is a high fidelity pathway which uses a template donor sequence to reverse a DSB. HR
commences upon DNA damage recognition and a cascade of signaling recruits proteins that
further resect the break to single stranded 3’ ends (Figure 3) [8]. The single stranded ends are
then coated with single stranded binding proteins, protecting the templates. These unbound ends
are then wrapped with Rad51, which is associated with BRCA1. With Rad51 bound, the single
stranded DNA participates in homology recognition [1]. The Rad51 complex also allows for
strand exchange. Subsequent branch migration and nucleotide polymerization from DNA
polymerase II occur. The whole complex then resolves itself with an exact copy of the template
homolog where the DSB occurred.
Goal
The goal of this work is to analyze if topoII/DNA damage complexes are repaired through
either HR or NHEJ. HR and NHEJ events resulting from poison damage can be quantified
through the use of a highly specific reporter cassette.
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Figure 3 - NHEJ [11] and HR [7] Pathways. NHEJ uses the Ku complex to recruit subsequent
proteins such as DNA-PKcs, ultimately resulting in blunt double strand ligation of the DSB. HR
is a high fidelity pathway that uses a donor sequence as a template, thus resulting in high fidelity
DNA retrieval.
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Chapter Two: Methods and Materials
Exposure of DR-GFP HeLa cells to Etoposide and ISce-I
Stably integrated DR-GFP (HR) HeLa cells were maintained in 1640 RPMI (Invitrogen)
supplemented with 10% fetal bovine serum (FBS) (Invitrogen) in a humidified 37oC with 5%
CO2 incubator. Cells were dispensed into three 12 well plate formats at 200,000 cells per well in
2 mL 1640 RPMI 10% FBS. Following 24 hours incubation, six of the twelve wells were
transfected with 1.2 g pISce-I and 3.6 L Lipofectamine Reagent 2000 (Invitrogen, Carlsbad,
CA), according to the manufacturer’s instructions for four hours in 1 mL of OPTI-MEM I
(Invitrogen). Next, the OPTI-MEM I was aspirated from the transfected wells and dispensed 2
mL 1640 RMPI 10% FBS, then incubated for 24 hours. After incubation, the 1640 RPMI from
all twelve wells were aspirated and 1 mL OPTI-MEM I was added to each well with the desired
concentration of VP16 from a 20 mM aliquot stock solution (TopoGEN). The cells were treated
with VP16 for one hour, then washed with 1 mL 1X PBS, and 2 mL of 1640 RPMI 10% FBS
was added. The 12 well plates were incubated for 24 and 72 hours to establish a time course for
recovery. At the end of each respective recovery incubation time, 200 L of 0.25% TrypsinEDTA (Invitrogen) was added and incubated for 5 minutes. Next, 200 L of 1640 RPMI
without FBS was added to neutralize the trypsin and 400 L of the cell suspension was
dispensed in 400 L 1X PBS in a 5 mL Fluorescence Activated Cell Sorter (FACS) tube
(FALCON). GFP was read using FACSCalibur and CellQuest software (BD Bioscience, San
Jose, CA).
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Screening of RYDR-GFP clones
HeLa cells were stably integrated with RY-DRGFP (RY-HR) plasmid (TopoGEN) by
Alex Fagenson, Dr. Muller laboratory. Twenty-four hours prior to transfection, the HeLa cells
were plated at a concentration of 5 x 105 cells per well in a six well plate. The HeLa cells were
transfected in six-well plates with Lipofectamine 2000 reagent according to manufacturer’s
instructions. Next, two μg of plasmid DNA, RY-DRGFP #1 and #6 respectively were transfected
in 1 mL OPTI-MEM I. Four hours following transfection, the media was aspirated and cells were
grown in 1640 RPMI 10% FBS for twenty four hours. Cells were then washed with 1X PBS,
trypsinized, and split into 10 cm culture dishes. Clones were subjected to single colony isolation
technique while being maintained in media containing puromycin (2 μg/mL) and grown until the
colonies were visible on the plate (~4 weeks). The 1640 RPMI 10% FBS media was changed
routinely for both plasmid cultures every four days. Colonies were then picked with a pipette tip
and placed in 48-well tissue cultured plates. Cells were incubated and forty eight clones of
plasmid #1 and #6 were maintained in 48 well formats until clone screening was performed.
Colonies were selected as single clones and were subcultured and grown up to expand
the clones. Healthy cells were plated in six, 12 well plates. One colony was placed per well in
two12 well plates. Approximately 200,000 cells per well were then plated and incubated for 24
hours with puromycin containing 1640 RPMI. Following this, 1 g pISce-I with Lipofectamine
Reagent 2000 was transfected into one of the 12 well plates according to manufacturer’s
instructions in 1 mL of OPTI-MEM I for five hours. The media was then aspirated and replaced
with 2 mL 1640 RPMI 10% FBS and incubated for 24, 72, and 144 hours. Using the
FACSCalibur and CellQuest software, GFP expression was calculated. The best clone was kept
for further projects, and the remaining clones were discarded.
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Confocal Microscopy.
Two 6 well plates were seeded with approximately 100,000 cells per well on top of
cover slips in four of the six wells and 2 mL of 1640 RPMI 10% FBS media. The plates were
then incubated for 24 hours at 37oC, 5% CO2, in a humidified incubator. The media was then
aspirated in wells one, three, and four and replaced with 1 mL OPTI-MEM I. To well one, 2 g
ISce-I and Lipofectamine Reagent 2000 for the non-inducible RY clone was added according to
manufacturer’s instructions for four hours, and 2 L of doxycycline for the inducible system was
incubated until harvesting. To well three and four, 5 M and 100 M of VP16 respectfully was
exposed to the cells for one hour. Following drug treatment, the media was aspirated and
replaced with 1640 RPMI 10% FBS and incubated for 24 and 48 hours to establish a time course.
After the desired incubation time, the media was aspirated and the cells were washed with 1X
PBS. Using a bent hypodermic needle, the cover slips were carefully removed. A 1.5 M PI
staining solution stained the cells for thirty minutes in the dark. The cover slips were then
washed with 1X PBS. Using FischerFinest Premium Slides, one drop of emulsion oil was placed
between the slide and the cover slip. A KimWipe was used to remove excess oil from around the
cover slip. Four drops of clear nail polish was dispensed and a ring was made around, not
overlapping with, the cover slip and allowed to dry for five minutes. Then two drops of clear
nail polish were placed on the edge of the cover slip and using the supplied brush, the nail polish
was gently made to overlap onto the cover slip. The slides were dried for five minutes. The
slides were then analyzed using a confocal microscope at 20X and 100X power.
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Analysis of GFP and Methylation in RY-HR Stably Integrated HeLa Cells Using VP16
Approximately 1.37 x 106 RY-HR HeLa cells per 100mm plate were incubated in 10 mL
of 1640 RPMI 10% FBS for a total of 9 plates. The colonies were incubated at 37 oC, 5% CO2,
and in a humidified incubator environment for two days. Making sure the cells were in heavy
exponential growth, 0.5 M and 5 M VP16 were added to two of the plates and exposed
continuously for five days until confluent. In four plates, 0.5 M, 5 M, 50 M, and 500 M of
VP16 were exposed for one hour in 2 mL OPTI-MEM I media, then aspirated, and replaced with
10 mL 1640 RPMI 10% FBS media and incubated for five days. One plate was left untreated,
and the last plate was exposed to 5 g of ISce-I for 4 hours with Lipofectamine Reagent 2000
according to the manufacturer’s instructions in 5 mL OPTI-MEM I. The media was then
aspirated and replaced with 1640 RPMI 10% FBS media and incubated for five days until
confluent. Using the FACSCalibur and CellQuest software GFP expression was read.
Trypan Blue Exclusion Assays for Cell Viability
RY-HR HeLa cells and NHEJ reporter HeLa cells were plated at approximately 500,000
cells per well and incubated for 2 days followed by treatment with increasing VP16
concentrations. Typically, the cells were exposed to VP16 for one hour. The cells were then
washed and incubated in 1640 RPMI 10% FBS medium for three days. After the three day
incubation, 180 L of 0.1% trypan blue dye was aliquot to microcentrifuge tube. The
supernatant of each well was saved in a 15 mL conical tube. The cells were trypsinized with 200
L of 0.25% Trypsin-EDTA (Invitrogen) and incubated for five minutes under humidified, 37oC,
5% CO2 incubator conditions. To neutralize the trypsin, 200 L of 1640 RPMI was added to the
trypsinized cells creating a pool of cells, which was then added to the supernatant. From the cell
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suspension, 20 L was added to the 180 L of 0.1% trypan blue dye. From that, 10 L of the
dyed cells was injected into a hemocytometer slide and viewed under a microscope. The slide is
divided into four quadrants and each of the four quadrants was counted and totaled. A ratio of
stained versus unstained cells indicates percentage cytotoxicity.
Analysis of Repair of Topoisomerase I and II DNA Damage by HR and NHEJ Pathways
Approximately 1x106 cells of both stably integrated RY-HR HeLa cells and inducible, stably
transfected NHEJ reporter cassette HeLa cells were plated in 11 plates for the RY-HR HeLa line
and 10 plates for the NHEJ HeLa line. The cells were incubated for three days in 5% CO 2, 37oC,
and humidified conditions. Following incubation, the cells were observed to be in exponential
growth. The plates were exposed to an increase in VP16 concentration, and an increase in
campothecin (CPT), a topoisomerase I poison for one hour in 2 mL of OPTI-MEM I. A positive
control and a transfection efficiency control were set up by the transfection of pISce-I and
pEGFP utilizing Lipofectamine 2000 reagent, according to manufacturer’s instructions. One
plate for both lines was left untreated and untransfected as a negative control. The plates were
then incubated for 3 days following the drug treatments. After incubation, the supernatant of the
plates was transferred to a 15 mL conical tube. The cells were then trypsinized with 1 mL 0.25%
Trypsin-EDTA (Invitrogen) for 5 minutes in 37OC, 5% CO2, and humidified incubator
conditions. The trypsin was then neutralized with 1 mL of 1640 RPMI without FBS, and 1 mL
of the trypsinized cells was added to 1 mL1X PBS in a 5 mL FACS tube (FALCON). The cells
were analyzed via FACSCalibur and CellQuest Pro (BD Software) for GFP expression.
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Doxycycline inducible ISce-I expression system
The inducible reporter system used for the NHEJ and HR HeLa cells lines were stably
integrated by Dr. Bongyong Lee. These reporters use a tetracycline induction system to
transcribe ISce-I endonuclease.

Doxycycline is a semi-synthetic tetracycline derivative.

Following exposure to doxycycline, the pCMV promoter sequence is exposed allowing for
transcription of the ISce-I downstream gene. Without doxycycline exposure, no ISce-I is
expressed.

11

B

Figure 4 – The RYDR-GFP and NHEJ Reporter Constructs. (A): RYDR-GFP reporter
system. The RY element and the ISce-I loci create DSBs when exposed to a topoII poison or
ISce-I restriction endonuclease respectively. The First cassette following a DSB searches for
homology amongst the second cassette, leading to HR repair of the DSB and GFP expression.
Before HR repair, cassettes 1 and II are incapable of expressing GFP due to mutations in the first
cassette and a stop codon in the second cassette. Following HR repair as dictated by the diagram,
cassette I can express GFP. (B): The NHEJ reporter system. The opposing ISce-I restriction cut
sites allow for direct ligation of the opposing cassettes initiating GFP expression. The RY
sequence is not needed due to the size of the NHEJ reporter system.
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Chapter Three: Results
HR analysis following VP16 drug treatments and transfection of ISce-I in HR HeLa cells
The treatment of stably integrated HR HeLa cells with VP16 served as an initial and
essential founding piece of information for the following results (Figure 5). The positive control
serves to illustrate the reporter system is working. The positive control, which includes the
transfection of ISce-I with no subsequent drug treatment, shows the potential of GFP expression.
The negative control consists of HR cells, lacking ISce-I transfection and drug treatment, serving
as a background reading and is ultimately subtracted from the corresponding ISce-I data point.
Although the anticipated GFP expression for the negative control should be 0%, the 0.1% GFP
finding is likely due to the nature of the integrated GFP cassettes.
The combination of VP16 with the transfection of ISce-I increased the GFP expression
by 1.3% in the 5 M etoposide range, and steadily declined with higher VP16 concentrations
thereafter (Figure 5). In addition, GFP expression gradually decreased over time with VP16
concentrations above 5 M. However, the remaining increasing VP16 and ISce-I exposures
were gradually decreased through both time and increasing VP16 concentration. This is likely
due to toxicity of the VP16 drug (IC50 = 200 M).
Following this data, a plasmid that narrows variability was used. The RYDR-GFP (RYHR) (Figure 4) cassette contains an ultra high affinity 56 base pair purine rich sequence for
topoII[10]. This high affinity topoII binding site should attract the endogenous topoII and
direct cleavages in this region 5’ of the ISce-I site in the presence of a drug such as VP16. As a
result, the cellular DNA damage repair system should be activated with the HR cassette. The
results show that HeLa cells are able to repair the VP16 initiated DSB up to 5 M concentration
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(Figure 6). Two exposure times of VP16 were allotted for the stably integrated RY-HR HeLa
cells. One batch of cells was exposed to VP16 for 5 days. The second batch was exposed to
VP16 for 1 hour and then allowed to recover. The positive control is solely a transfection of
ISce-I plasmid while the negative controls represent GFP expressed in the absence of ISce-I and
drug treatment. There is a clear trend with increasing concentration of VP16 treatment in both
the prolonged and short drug exposure time frames (Figure 6). During the five day exposure,
there is an increase of GFP beyond the positive control. The one hour drug treatments also had
an increasing trend with increased dosage of VP16 (Figure 6). The data suggest that the
presence of the RY element is stimulating HR in the GFP reporter through VP16 drug treatment.
In this analysis, cells were treated at low to high levels of VP16 for a total of 5 days or with the
same concentration for 1 hour followed by 5 days of recovery. In both cases, it is clear that
VP16 is inducing the formation of WT GFP+ cells at certain concentrations (0.05 – 50 M).
Higher concentrations were toxic to the cells. As a result of this, we decided that a morphological
investigation of the GFP expressed in HR, RY-HR, and NHEJ HeLa cells was required.
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Figure 5 - HR in VP16 Treated HR HeLa Cells. Stably integrated HR HeLa cells were
transfected with ISce-I and treated with VP16 for 1 hour as described in the “Materials and
Methods.” In a twelve well format, approximately 200,000 cells were seeded per well and
incubated for 24 hours. Transfection of ISce-I for 4 hours occurred in the necessary wells for
four hours. The cells were then incubated for 24 hours and a 1 hour VP16 drug treatment
ensued. A time course for recovery for 72 hours (**p<0.01) was read for GFP expression using
FACS analysis. Error bars symbolize data range after three replicated trials.
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**

Figure 6 - HR in VP16 Treated RY-HR HeLa Cells. Stably integrated RY-HR HeLa cells
were seeded at approximately 1.37 x 106cells per plate and incubated for 24 hours. Following
incubation, drug treatments lasting for the indicated time (5d = 5 days, 1h = 1 hour) at the stated
VP16 concentrations. One hour drug treated cells were washed with 1X PBS, then incubated for
5 days. The positive control was transfected with ISce-I for four hours, and recovered for 5 days.
All cells were harvested simultaneously for GFP analysis via FACS (**p<0.4). Error bars
symbolize data range after three replicated trials.
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Figure 7 - Confocal Microscopy of RY-HR HeLa Cells. Stably integrated RY-HR HeLa cells
were seeded over a cover slip and incubated for 24 hours. Following incubation, 5 M VP16 (A)
and 100 M VP16 (B) was exposed to the cells for one hour. The cells were then washed with
1X PBS and incubated for 2 days. The cover slips were then removed and stained with a PI
staining solution for 30 minutes. The cover slips were washed then adhered onto a slide using
nail polish. Confocal microscopy was viewed with fluorescence for GFP and PI. (A) and (B)
were captured at 20X magnification.
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Confocal Microscopy
Confocal microscopy was performed to examine GFP expressing cells morphologically
(Figure 7 – 8). The GFP protein appears to well distributed throughout the cell in the RY-HR
cultures treated with VP16 for one hour followed by a 48 hour recovery interval. At 100 M
VP16 there is an obvious toxic effect. Confocal analyses were performed on the doxycycline
inducible NHEJ and HR reporter cells; see “Materials and Methods.” This experiment was
preformed to examine any cytological differences between these two reporter systems. The
NHEJ reporter yielded cells with GFP distributed throughout the cell (Figure 8). In contrast, the
GFP produced as a result of HR in the HR clones appears largely in the nucleus, possibly due to
a nuclear localization sequence on the GFP.
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Figure 8 - Confocal Microscopy of HR and NHEJ HeLa Cells. Stably integrated doxycycline
inducible NHEJ and HR HeLa cell lines were seeded at approximately 200,000 cells per well in
a 12 well plate with an inherent slide base. Following 1 day incubation, doxycycline was added
to the stated wells. The cells were incubated with the doxycycline for 3 days. (A) shows the
uninduced HR HeLa cells at 20X zoom. (B) shows doxycycline induced HR HeLa cells at 20X
zoom. (C) shows doxycycline induced NHEJ reporter system integrated HeLa cells at 20X
zoom. (D) shows cells from (C) at 100X zoom. The confocal microscope was set to fluoresce
solely GFP.

19

Stably Integrated, DOX Inducible
NHEJ Reporter HeLa cells

Stably Integrated RY-HR Reporter
HeLa Cells

Figure 9 - Cytotoxicity for NHEJ and RY-HR HeLa Cells. Cytotoxicity percentages were
calculated for stably integrated inducible NHEJ reporter systems in HeLa cells and stably
integrated RY-HR HeLa cells. Both cultures were plated at 500,000 cells per well and incubated
for 48 hours. Drug treatments lasted for one hour with both VP16 and CPT (TopoI Poison). The
cells were then washed and allotted a recovery interval of 48 hours. Cytotoxicity percentages
were calculated using trypan blue exclusion assays.
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Figure 10 - HR and NHEJ After VP16 Treatments (A). illustrates GFP expression from
doxycycline inducible stably integrated NHEJ reporter cassettes in HeLa cells. (B) shows stably
integrated RY-HR HeLa cells. Both cell lines were plated at 500,000 cells per well and
incubated for 48 hours. Drug treatments lasted for one hour for both VP16 and CPT (TopoI
poison). For the positive controls; ISce-I transfection lasted for four hours and 3 day exposure for
the inducible NHEJ system. The drug treated cells recovered for 3 days and were analyzed for
GFP expression using FACS. Transfection efficiency was measured by pEGFP (18%).
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Analysis of Toxicity
The results of the trypan blue exclusion assay shows that with increasing concentration of
VP16, there is an increase in cytotoxicity as expected (Figure 9). VP16 is a known
chemotherapeutic and thus should have the high toxicity rating as shown in these results. CPT, a
highly specific TopoI poison, shows an increased cytotoxicity amongst the NHEJ reporter
system with concentrations from 0.5 – 50 M being toxic. The RY-HR HeLa cells show
increased resistance to CPT. The RY-HR toxicity data does show that VP16 is generally less
cytotoxic than CPT with regard to HR.
Analysis of Repair of Topoisomerase I and II DNA Damage by HR and NHEJ Pathways
There are two major DSB repair pathways in animal cells; HR and NHEJ (see
“Introduction”). Since we have dedicated reporters for each pathway and given that the drugs
are highly specific for topoI (CPT) or topoII (VP16) mediated DNA damage, the repair process
was evaluated in each case (Figure 10). Figure 10-A, the NHEJ reporter system, shows there is
an increase in susceptibility in CPT damage and mild reparability in exposure to VP16 with
dose dependent decrease in GFP. The positive control is noticeably elevated in comparison to
the remaining samples. There is a decrease in NHEJ repair with an increase in VP16
concentration. Figure 10-B shows the effects of CPT and VP16 on RY-HR HeLa cells. There
is an increase in HR with an increase in VP16 concentration and the opposite trend with CPT
concentration. In both instances, 50 M of CPT or VP16 caused toxicity in the culture. The
data points show that VP16 and CPT HR repair gives a GFP reading close to that of the positive
control, ISce-I transfection.

22

Chapter Four: Discussion
This project utilizes reporter cassettes to analyze the repair of DNA damage induced by
topoIIand topoI poisons. Specific cassettes have been employed that report repair of DSBs by either
HR or NHEJ (Figure 4). The first cassette, in the case of RY-HR cultures, contains the topoII hot

spot for the topoIIpoison and/or an ISce-I restriction endonuclease cut site. The second
cassette contains the template sequence to repair the induced DSB in the first cassette. Without
drug treatment or transfection GFP is transcribed but not expressed due to mutations in the first
sequence and a stop codon in the second sequence. The NHEJ pathway is being specifically
measured using the NHEJ reporter (Figure 4) because the formation of wild type GFP cannot
proceed by HR due to the lack of a homologous donor sequence.
The RY-HR GFP reporter systems indicate that with an increase in VP16 concentrations
to 5 M (Figure 10 - B), there is an increase in HR repair. A dose dependent decrease in the
NHEJ pathway (Figure 10 – A) in response to VP16 is also observed. The RY-HR integrated
cells showed a dose dependent decrease in HR treated with CPT (Figure 10-B). The DSB
initiated by VP16 appears to be repaired through the high fidelity, error free HR pathway. The
high mitotic activity of cancer cells could make the cell cycle dependent HR repair pathway
preferential compared to the non-cell cycle dependent NHEJ pathway. Most healthy cells are in
the resting G1/G0 phase thus not prone to HR DSB repair.
The data in Figure 9 define the toxicity profile of VP16. The highly specific topoI
poison CPT had a higher toxicity than the VP16. HR may well be the preferred DSB repair
pathway because the cancer cells are constantly dividing and HR is cell cycle specific.
Moreover, HR proteins are associated with specific cell cycle checkpoints, whereas NHEJ is
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not [14]. Due to the high mitotic levels of most cancer cells, HR should be a prominent
pathway for break repair. However, not all cancer cell types follow the HR pathway
preferentially. For example, both normal and malignant urothelial cells upregulate the NHEJ
pathway, while HR is more dominant in cervical cancer cells [15]. The data and literature
suggest that DSB repair pathways are highly variable and may well be dependent on tumor
tissue location. Most importantly, since healthy cells preferentially use NHEJ to repair DSBs, a
selective agent for HR proteins could sensitize cells to anti-cancer treatments while leaving
healthy cells relatively unharmed. One report demonstrated that NHEJ targeting sensitized
tumor cells and caused normal cell damage [16]. The targeting of HR could lessen the
malevolent impact of chemotherapy on healthy cells, and thereby target cancer cells selectively.
Future work for this project includes analyzing, through the same reporter constructs,
the effects of VP16 and CPT drug treatments on cell lines known for specific repair pathway
upregulation. For instance, B cell lines are highly associated with NHEJ pathways. In addition,
topoII analysis can be preformed based on the two pathways. TopoII has been found to be a
causative enzyme of secondary malignancies in patients served topoII poisons. Finally,
knockout or over expression of specific proteins upregulated in HR such as BRCA1 can be
explored for its effects on both pathways via the GFP system.

24

References
1.

Hinz, J. M. (2010), Role of homologous recombination in DNA interstrand crosslink
repair. Environmental and Molecular Mutagenesis, 51: 582–603. doi: 10.1002/em.20577

2.

Yves Pommier (2010), DNA Topoisomerases and Their Poisoning by Anticancer and
Antibacterial Drugs. Chemistry & Biology 17, May 28, 2010.

3.

Gun E. Lee, Joo Hee Kim, Michael Taylor, and Mark T Muller (2010). DNA
Methyltransferase 1 Associated Protein Is a Corepressor That Stimulates DNA
Methylation Globally and Globally at Sites of DSB Repair. JBC, M110.148536

4.

Zhang, Ailing (2006). A protease pathway for the Repair of Topoisomerase II-DNA
covalent complexes. JBC Volume 281, Number 47 pg 35997.

5.

Azarova (2007). Roles of DNA topoisomerase II isozymes in chemotherapy and
secondary malignancies. JBC Vol 104 no 26.

6.

Pommier, Y, Leo E, Zhang H, Marchand C (2010). DNA topoisomerases and their
poisoning by anticancer and antibacterial drugs. Chem Biol. 2010 May 28;17(5):421-33.

7.

Concetta Cuozzo, Muller MT, Avvedimento EV (2007). DNA Damage, Homology –
Directed Repair and DNA Methylation. PLOSGenetics Vol 3, Issue 7 e110.

8.

Watson, Baker, Bell, Gann, Levine, Losick (2008). Molecular Biology of the Gene.
Pearson Education. 6 ed

9.

Junko Iijima, Zhihong Zeng, Shunichi Takeda, and Yoshihito Taniguchi (2010). RAP80
Acts Independently of BRCA1 in Repair of Topoisomerase II Poison-Induced DNA
Damage. Cancer 70(21).

25

10.

J R Spitzner, I K Chung, and M T Muller (1990). Eukaryotic topoisomerase II
preferentially cleaves alternating purine-pyrimidine repeats. Nucleic Acid Res. 18(1): 1–
11

11.

Sandeep Burmaa, Benjamin P.C. Chena and David J. Chen (2006). Role of nonhomologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair
Volume 5, Issues 9-10, 8 September 2006, Pages 1042-1048.

12.

Emil Mladenova and George Iliakis (2011). Induction and repair of DNA double strand
breaks: The increasing spectrum of non-homologous end joining pathways. Mutation
Research/Fundamental and Molecular Mechanisms of Mutagenesis.
doi:10.1016/j.mrfmmm.2011.02.005.

13.

J. Thomas Holthausena, Claire Wymana, and Roland Kanaar (2010). Regulation of DNA
strand exchange in homologous recombination. DNA Repair. Volume 9, Issue 12, 10
December 2010, Pages 1264-1272

14.

Shrivastav M, De Haro LP, and Nickoloff JA (2008). Regulation of DNA double-strand
break repair pathway choice. Cell Res 18, 134-147.

15.

Windhofer F, Krause S, Hader C, Schulz WA, and Florl AR (2008). Distinctive
differences in DNA double-stranded break repair between normal urothelial and
urothelial carcinoma cells. Mutat Res 638 56 – 65.

16.

Kim CH, Park SJ, and Lee SH (2002). A targeted inhibition of DNA-dependent protein
kinase sensitizes breast cancer cells following ionizing radiation. J Pharmacol Exp Ther
303, 753-759.

26

17.

Mao Zhiyong, Jiang Ying, Liu Xiang, Seluanov Andrei, and Gorbunova Vera (2009)
DNA repair by homologous recombination, but not by nonhomologous end joining, is
elevated in breast cancer cells. Neoplasia 11, 683 – 691.

27

